Trial Profile
AVANTI - Avelox in Acute Exacerbations of Chronic Bronchitis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2013
Price :
$35
*
At a glance
- Drugs Moxifloxacin (Primary)
- Indications Acute exacerbations of chronic bronchitis; Bacterial infections
- Focus Therapeutic Use
- Acronyms AVANTI
- Sponsors Bayer
- 07 Jul 2012 Actual patient number (2672) added as reported by ClinicalTrials.gov.
- 03 Feb 2011 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
- 03 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.